229 related articles for article (PubMed ID: 28938918)
1. Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.
De Wolf K; Rottey S; Vermaelen K; Decaestecker K; Sundahl N; De Lobel L; Goetghebeur E; De Meerleer G; Lumen N; Fonteyne V; De Maeseneer D; Ost P
Radiat Oncol; 2017 Sep; 12(1):157. PubMed ID: 28938918
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
[TBL] [Abstract][Full Text] [Related]
3. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.
Hepel JT; Leonard KL; Safran H; Ng T; Taber A; Khurshid H; Birnbaum A; ; Wazer DE; DiPetrillo T
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1021-1027. PubMed ID: 27745983
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): A multiarm Phase I trial.
Deodato F; Macchia G; Cilla S; Ianiro A; Sallustio G; Cammelli S; Buwenge M; Mattiucci GC; Valentini V; Morganti AG
Br J Radiol; 2019 Feb; 92(1094):20180422. PubMed ID: 30325662
[TBL] [Abstract][Full Text] [Related]
6. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
Grassi P; Verzoni E; Ratta R; Porcu L; Prisciandaro M; Mennitto A; Calareso G; de Braud F; Procopio G
Drugs R D; 2017 Sep; 17(3):461-467. PubMed ID: 28801802
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Brade AM; Ng S; Brierley J; Kim J; Dinniwell R; Ringash J; Wong RR; Cho C; Knox J; Dawson LA
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):580-7. PubMed ID: 26867886
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.
Stinauer MA; Kavanagh BD; Schefter TE; Gonzalez R; Flaig T; Lewis K; Robinson W; Chidel M; Glode M; Raben D
Radiat Oncol; 2011 Apr; 6():34. PubMed ID: 21477295
[TBL] [Abstract][Full Text] [Related]
9. 4π noncoplanar stereotactic body radiation therapy for head-and-neck cancer: potential to improve tumor control and late toxicity.
Rwigema JC; Nguyen D; Heron DE; Chen AM; Lee P; Wang PC; Vargo JA; Low DA; Huq MS; Tenn S; Steinberg ML; Kupelian P; Sheng K
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):401-9. PubMed ID: 25482301
[TBL] [Abstract][Full Text] [Related]
10. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Shaib WL; Hawk N; Cassidy RJ; Chen Z; Zhang C; Brutcher E; Kooby D; Maithel SK; Sarmiento JM; Landry J; El-Rayes BF
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):296-303. PubMed ID: 27475674
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World.
Gebbia V; Girlando A; DI Grazia A; Fazio I; Borsellino N; Piazza D; Serretta V; Pergolizzi S; Pontoriero A; Firenze A; Valerio MR
Anticancer Res; 2020 Dec; 40(12):7037-7043. PubMed ID: 33288600
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
14. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
15. A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer.
Kainuma T; Kawakami S; Tsumura H; Satoh T; Tabata KI; Iwamura M; Hayakawa K; Ishiyama H
Radiat Oncol; 2019 Sep; 14(1):158. PubMed ID: 31477122
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
17. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma.
Kim JW; Seong J; Lee IJ; Woo JY; Han KH
Oncotarget; 2016 Jun; 7(26):40756-40766. PubMed ID: 27213593
[TBL] [Abstract][Full Text] [Related]
20. A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Haas RL; Gelderblom H; Sleijfer S; van Boven HH; Scholten A; Dewit L; Borst G; van der Hage J; Kerst JM; Nout RA; Hartgrink HH; de Pree I; Verhoef C; Steeghs N; van Coevorden F
Acta Oncol; 2015; 54(8):1195-201. PubMed ID: 25920360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]